

COPY

PATENT

Customer No. 22852

Attorney Docket No. 1197-227

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Shaun Jordan et al.

Application No.: 10/055,915

Filed: January 28, 2002

For: 5-HT_{1A} Receptor Subtype Agonist

Commissioner for Patents
Washington, DC 20231

Sir:

) Group Art Unit: 1614

) Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Enclosed for the consideration of the Examiner in connection with the prosecution of this case is a copy of the Search Report issued in the corresponding International patent application together with a copy of each of the cited references and a Form PTO 1449.

Each item of information in this statement was cited in a communication from a foreign patent office in a counterpart foreign application less than three months ago.

If there is any fee due in connection with the filing of this statement, please charge such fee to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

Arthur S. Garrett

Reg. No. 20,338

Dated: December 23, 2002

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

462141_1.DOC

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	1197-227	Appln. No.	10/055,915
Applicant	Shaun Jordan et al.		
Filing Date	January 28, 2002	Group:	Not Yet Assigned

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	4,764,416	08/16/88	Ueyama et al.	428	212	
	5,691,330	11/25/97	Nakao et al.	514		

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	09 301867	11/25/97	Japan			YES - Abstract
	0 367 141	05/09/90	EPO			YES
	WO 92/20655	11/26/92	WIPO			YES
	WO 94/09765	05/11/94	WIPO			YES
	WO 94/13620	06/23/94	WIPO			YES
	WO 98/08817	03/05/98	WIPO			YES
	WO 99/38864	08/05/99	WIPO			YES

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Eric P.M. Prinssen et al., Interactions between neuroleptics and 5-HT _{1A} ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects, " Psychopharmacology, Vol. 144, No. 1, May 1999 (1999-05), pages 20-29.
	Uwahodo Yasufumi et al., "Pharmacological profile of OPC-14597, a novel antipsychotic drug (2); Weak extrapyramidal side effects." Japanese Journal of Pharmacology, Vol. 67, No. Suppl. 1, 1995, page 144P
	S. Jordan et al., "In Vivo Effects of Aripiprazole on Dopaminergic and Serotonergic Function in Rat Prefrontal Cortex and Striatum." Society for Neuroscience Abstracts, Society of Neuroscience, US, Vol. 2., No. 27, 2001, page 2327, AN87503
	Jeffery A. Lieberman, "Atypical Antipsychotic Drugs as a First-Line Treatment of Schizophrenia: A Rationale and Hypothesis," Journal of Clinical Psychiatry, Vol. 57, No. Suppl. 11, 1996, pages 68-71.
	Paul E. Keck, Jr., et al., "Bipolar Disorder," Medical Clinics of North America, W. B. Saunders Company, Philadelphia, US., Vol. 3, No. 85, May 2001 (2001-05), pages 645-661
	Maria-Garcia-Anaya et al., Los antipsycoticos atipicos: Una Revisión, Salud Mental, Vol. 24, No. 5, October 2001 (2001-10), pages 37-43

RECEIVED
SEP 9 2003
TECH CENTER 1600/2900

dup licate

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	1197-222	Appln. No.	10/055,915
Applicant	Shaun Jordan et al.		
Filing Date	January 28, 2002	Group:	Not Yet Assigned
Examiner	Date Considered		
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce		

462095_1.DOC